Related Experiment Video
Updated: Jan 8, 2026
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer
Valérie Janelle1, Marie-Pierre Langlois, Esther Tarrab
1Authors' Affiliations: Biomed Research Center, Department of Biology, Université du Québec à Montréal, Montréal, Québec, Canada.
Abstract:
Although the role of the complement system in cancer development has been studied, its involvement in the development of an antitumoral immune response remains poorly understood. Using cobra venom factor (CVF) to inhibit the complement cascade via C3 molecule exhaustion in immunocompetent mice bearing B16gp33 melanoma tumors, we show that transient inhibition of the complement system allowed for the development of a more robust gp33-specific antitumoral CD8(+) T-cell response. This immune response proved to be natural killer (NK) dependent, suggesting an interaction of complement proteins with this cellular subset leading to T lymphocyte activation and enhanced cytotoxic T-cell activity against tumor cells. This study demonstrates for the first time the implication of the complement system in the development of NK-mediated cytotoxic T-cell-dependent antitumoral immune responses. The complement pathway could therefore be a potent therapeutic target to improve NK-dependent antitumoral immune responses in patients with cancer.
Insights
Transiently inhibiting the complement system enhances natural killer (NK) cell-dependent CD8(+) T-cell responses against melanoma tumors. This suggests complement inhibition as a therapeutic strategy for improving cancer immunity.
Area of Science:
- Immunology
- Oncology
- Complement System Biology
Background:
- The complement system's role in cancer development is known, but its impact on anti-tumor immunity is unclear.
- Understanding complement's influence on immune responses is crucial for developing novel cancer therapies.
Purpose of the Study:
- To investigate the involvement of the complement system in the development of anti-tumor immune responses.
- To explore the potential of complement inhibition as a therapeutic strategy in cancer immunotherapy.
Main Methods:
- Utilized cobra venom factor (CVF) to induce complement C3 molecule exhaustion in mice with B16gp33 melanoma tumors.
- Assessed the impact of complement inhibition on gp33-specific CD8(+) T-cell responses and NK cell activity.
Main Results:
- Transient complement inhibition led to a more robust gp33-specific anti-tumor CD8(+) T-cell response.
- The enhanced immune response was dependent on natural killer (NK) cells, indicating their interaction with complement.
- Demonstrated complement's implication in NK-mediated, T-cell-dependent anti-tumor immunity.
Conclusions:
- The complement system plays a significant role in regulating NK-mediated cytotoxic T-cell anti-tumor immune responses.
- Targeting the complement pathway offers a promising therapeutic approach to enhance NK-dependent anti-tumor immunity in cancer patients.
